(2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide CAS NO.1217486-61-7

Anhui Haikang Pharmaceutical Co.,
Ltd. is a collection of scientific
research,production and sales
High-Tech Enterprise,which
established in 2009,and covers an
area of 28,000 ㎡.Company locates
in Anqing city,on the bond of
Yangtze River, invested 80 million
RMB to set up synthesis workshops
and clean workshops.All the
productions strictly conform to GMP
standard and equipped with
high-class R&D center.The first
branch was founded in 2010,called
Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

BYL719 (>270mg/d) showed statistically significant dose-dependent anti-tumor efficacy in PIK3CA mutant xenograft rodent models. BYL719 has a low clearance rate, a half-life of 8.5 hours, and its effect is proportional to the increase of Chemicalbook between 30mg/d and 450mg/d, showing low individual differences in human Cmax and AUC. BYL719 (270mg/d) showed signs of clinical efficacy for the first time, including a partial response confirmed in ER+ breast cancer patients, and 8 out of 17 patients achieved significant PET response (PMR) and/or tumor cure.

Development prospects The industry is also very optimistic about the business prospects of Ozamod. Dr. Stephen Hanauer, medical director of the Northwestern Medical Digestive Health Center, said: "The data of the consolidation period of the trial and the previously reported induction period data indicate that the oral drug Ozamod is expected To help patients with moderate to severe ulcerative Chemicalbook ulcerative colitis. Ozamod is mainly used for the treatment of multiple sclerosis, ulcerative colitis and Crohn’s disease. Among them, multiple sclerosis and ulcerative colitis are not only long-term , The morbidity rate is high, and long-term medication is needed. It can be seen that Ozamod has a huge market capacity and promising prospects.